Logo

HYMOVIS® is a product developed by Fidia R&D, a leading company for over 60 years in the field of studying and developing patented hyaluronic acid. HYMOVIS®, whose active ingredient is HYADD®4 (hexadecylamide derivative of hyaluronic acid), exhibits a viscoelastic effect and a complete structural recovery even after repeated mechanical stress, thanks to the patented MO.RE. (MObile REticulum) TECHNOLOGY1

HYADD®4

HYADD®4 is an innovative hyaluronic acid hydrogel developed by Fidia Farmaceutici, marketed under the brand name HYMOVIS®. This advanced formulation features a unique hexadecylamide derivative of hyaluronic acid, enhancing its viscoelastic properties and prolonging its residence time in the joint
HYADD®4 is designed to provide effective viscosupplementation, improving joint lubrication and cushioning, which can significantly alleviate pain and improve mobility in still very active patients with osteoarthritis.

Clinical studies have demonstrated its efficacy in reducing symptoms and enhancing the quality of life for high demand patients with OA.

The hydrogel is administered via intra-articular injection, offering a promising alternative for those who have not responded well to conventional treatments.

WHAT IS HYMOVIS®?

HYDROGEL

4th generation intra-articular HA based product1

HYADD®4

Hexadecylamide of highly purified natural sodium hyaluronate obtained by bacterial fermentation2

MO.RE. (MObile REticulum) TECHNOLOGY

A network stabilized by reversable hydrophobic interactions, conferring high viscoelasticity and stability to 500-730 kDa MW HA derivative1

Discover why is good for you

Thanks to the exclusive MO.RE. Technology, which is the Mobile Reticulum technology (an exclusive patent of Fidia Farmaceutici), Hymovis® has different key advantages:
  • Enhanced Viscoelastic Properties: MO.RE. Technology helps maintain the viscoelastic properties of the product, which is crucial for its effectiveness in joint lubrication and cushioning3.
  • Structural Recovery: The technology allows the product to reconstruct its spatial structure even after repeated mechanical stress, ensuring long-lasting performance1.
  • Improved Rheology: MO.RE. Technology aids in the restoration of the product’s rheological properties, which is important for its flow and deformation behavior under stress1.

Composition

HYADD®4:

(hexadecylamide of highly purified natural sodium hyaluronate obtained by bacterial fermentation)2
24 mg/3mL

Available
Presentation

Box containing 2
pre-filled syringes2

Indications

HYMOVIS® is indicated to reduce pain and improve function in osteoarthritic joints and in the conservative treatment of the meniscal lesion of the knee2

Dosage &
Administration

  •  A treatment cycle in osteoarthritic joints consists of 2 injections administered at 1 week interval2
  •  A treatment cycle in joints with meniscal lesion consists of 2 injections administered at 2 weeks interval.

PRODUCT PORTFOLIO

VISCOSUPPLEMENTATION

Medical Devices CE0459.
Read the instructions for use carefully.

References:
1. Finelli I, et al. A new viscosupplement based on partially hydrophobic hyaluronic acid: A comparative study. Biorheology 48 (2011)263–275.
2. Hymovis® IFU
3. Bernetti A, et al. New Viscoelastic Hydrogel Hymovis® MO.RE. Single Intra-articular Injection for the Treatment of Knee Osteoarthritis in Sportsmen: Safety and Efficacy Study Results. Front. Pharmacol. 12:673988. doi: 10.3389/fphar.2021.673988.

You are about to leave fidiajointcare.com

All information you are about to see is related to a specific selected market, including the products’ portfolio, and therefore comply to different local regulations.

Proceed